Holen Sie sich die Stockscreener-App
639.43
0.66%
4.21
Vorhandelsmarkt:
646.10
6.67
+1.04%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$635.22
Offen:
$639.5
24-Stunden-Volumen:
6.85M
Relative Volume:
1.59
Marktkapitalisierung:
$605.19B
Einnahmen:
$53.26B
Nettoeinkommen (Verlust:
$13.80B
KGV:
41.79
EPS:
15.3
Netto-Cashflow:
$-50.20M
1W Leistung:
-16.52%
1M Leistung:
-19.37%
6M Leistung:
-26.75%
1J Leistung:
-27.70%
1-Tages-Spanne:
$629.40
$646.18
1-Wochen-Bereich:
$623.78
$763.00
52-Wochen-Spanne:
$623.78
$972.53
Lilly Eli Co Stock (LLY) Company Profile
Firmenname
Lilly Eli Co
Sektor
Telefon
(317) 276-2000
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Vergleichen Sie LLY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
639.43 | 569.45B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
172.78 | 418.62B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
198.64 | 350.91B | 58.33B | 3.76B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
119.31 | 229.50B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
80.30 | 199.90B | 63.62B | 16.41B | 14.72B | 6.49 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Herabstufung | Erste Group | Buy → Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-09-13 | Fortgesetzt | Citigroup | Buy |
| 2024-08-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Herabstufung | DZ Bank | Buy → Hold |
| 2024-02-16 | Bestätigt | Morgan Stanley | Overweight |
| 2023-12-21 | Herabstufung | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-20 | Fortgesetzt | UBS | Buy |
| 2023-08-09 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-26 | Bestätigt | Citigroup | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-24 | Bestätigt | BofA Securities | Buy |
| 2023-05-24 | Bestätigt | UBS | Buy |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-15 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-09-22 | Hochstufung | UBS | Neutral → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-03-10 | Eingeleitet | Daiwa Securities | Outperform |
| 2022-01-21 | Hochstufung | DZ Bank | Hold → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-16 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-16 | Bestätigt | BofA Securities | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-11 | Hochstufung | Berenberg | Hold → Buy |
| 2021-09-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-05 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-06-24 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-09-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-21 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-18 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-04-24 | Hochstufung | Edward Jones | Hold → Buy |
| 2019-04-11 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2019-01-23 | Eingeleitet | UBS | Buy |
| 2018-11-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-10-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-10-01 | Bestätigt | SunTrust | Buy |
| 2018-09-26 | Fortgesetzt | JP Morgan | Overweight |
Alle ansehen
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Eli Lilly's Mounjaro to land in Korea, setting off price war with Wegovy - Korea JoongAng Daily
Eli Lilly Faces US Lawsuit Over Bribery Allegations - MarketScreener
Texas sues, accusing Eli Lilly of 'bribing' physicians to prescribe GLP-1s - Houston Chronicle
These Eli Lilly executives have been scooping up stock after its big drop - MarketWatch
Texas sues Eli Lilly for allegedly bribing providers to push weight loss medications - Dallas News
Texas AG sues Eli Lilly for allegedly bribing medical providers to prescribe Lilly drugs - IndyStar
Texas sues Eli Lilly & Co. for bribing providers to prescribe medications - WISH-TV
Eli Lilly Executives and Directors Engage in Significant Stock Transactions - TradingView
Eli Lilly pledges vigorous defense as Texas sues over alleged drug kickbacks - Fierce Pharma
Texas AG: Eli Lilly and Co. offered kickbacks to providers to prescribe blockbuster drugs - The Indiana Lawyer
Texas Accuses Eli Lilly of Inducing Providers to Prescribe Drugs - Bloomberg Law News
Eli Lilly: The Bears Have Spoken Loud And Clear (Upgrade) (NYSE:LLY) - Seeking Alpha
Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications - Reuters
Texas Sues Eli Lilly (LLY) for Allegedly Bribing Doctors to Prescribe Its Drugs - TipRanks
Texas Sues Eli Lilly Over Bribery Allegations: Retail Focuses On Company’s Upbeat Performance By Stocktwits - Investing.com India
Texas Sues Eli Lilly Over Bribery Allegations: Retail Focuses On Company’s Upbeat Performance - Stocktwits
Eli Lilly Sued by Texas for Allegedly Bribing Providers to Prescribe Its Medications - MarketScreener
Eli Lilly's Legal Battles and the Future of Big Pharma's Profitability - AInvest
Eli Lilly sued in Texas suit over illegal kickbacks (LLY) - Seeking Alpha
Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications By Reuters - Investing.com
Texas Sues Eli Lilly for Allegedly Bribing Providers to Prescribe Its Medications - U.S. News & World Report
Eli Lilly & Co. (LLY) sued by Texas for allegedly bribing providers to prescribe company's medications - StreetInsider
Hims & Hers Remains Outside Novo Nordisk's Growing Legal Storm For Now - Benzinga
UK Government, Eli Lilly Partner To Target Obesity Health Gaps - inkl
1 Reason to Buy Eli Lilly (LLY) Stock - The Motley Fool
If You'd Invested $1,000 in Eli Lilly (LLY) Stock 5 Years Ago, Here's How Much You'd Have Today - Mitrade
Cramer Expects This FinTech To Reach $100, Upset With Eli Lilly: 'Come Back And Talk To Me' - Benzinga
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Aug 2025) - 24/7 Wall St.
3 ways the GLP-1 market has changed shape this year - Pharma Voice
Best Stock to Buy: Eli Lilly Stock vs. Novo Nordisk Stock - The Globe and Mail
US Personalized Medicine Market Trends and Company Analysis Report 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La Roche - Yahoo Finance
Eli Lilly, Pfizer Seek Spot in China Private Insurance Catalog - Bloomberg
Wall Street punishes Eli Lilly (LLY) over clinical trials, ignoring record milestones - Investorsobserver
Lilly’s Mounjaro Exhibits Heart Benefits In Type 2 Diabetes Landmark Trial - Insider Monkey
Why Eli Lilly’s (LLY) Tasty Q2 Earnings Left a Bitter Aftertaste - TipRanks
PRIMECAP Management's Strategic Moves: Significant Reduction in Eli Lilly and Co - Yahoo Finance
Alzheimer’s disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therape - Barchart.com
Eli Lilly expansion part of Bristol tax district in addition to state incentives - AOL.com
Why Eli Lilly Stock Popped Today - The Motley Fool
Analysts Reaffirm Buy Ratings on Eli Lilly After Stock Suffers Worst Decline Since 2008 - TipRanks
Are More Challenges Ahead for Eli Lilly After Earnings Beat? - ETF Database
Eli Lilly’s daily GLP-1 pill shows strong weight loss results without food restrictions - The Times of India
Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts - Benzinga
Wisconsin to give Eli Lilly up to $100M in tax credits for $3B expansion - AOL.com
Tesla, Eli Lilly Lead Market Cap Stock Movers on Monday By Investing.com - Investing.com Australia
Tesla, Eli Lilly Lead Market Cap Stock Movers on Monday - Investing.com
Can Eli Lilly Keep Up as NVO Eyes First Oral Obesity Pill Approval? - Yahoo Finance
Eli Lilly stock drops 14% despite earnings beat as Orforglipron data disappoints - Investing.com
Leerink Downgrades Eli Lilly and Company (LLY) to Market Perform From Outperform - Insider Monkey
Eli Lilly’s Mounjaro shown to provide cardiovascular protection in type 2 diabetes patients - PMLiVE
Analyst recommendations: Adobe, Airbnb, Eli Lilly, Lululemon, Lyft… - MarketScreener
Finanzdaten der Lilly Eli Co-Aktie (LLY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.60%
0.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):